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as reservoirs for intracellular bacteria 
during the acute tissue infection.
The data suggest that this could 
be a mechanism to avoid antibiotic 
eradication, which might explain why 
a high bacterial load was present even 
in tissues collected after prolonged 
intravenous antibiotic therapy. The 
authors also note that the localization 
of GAS varied and depended on the 
severity of tissue infection; intracellular 
localization was most frequent in 
noninﬂ  amed tissue, which also had a 
low bacterial load. Osterlund’s study had 
already shown that intracellular GAS 
was present in pharyngeal epithelial and 
macrophage-like cells of patients with 
tonsillitis. However, the current study by 
Thulin and colleagues shows for the ﬁ  rst 
time that this occurred in vivo during 
severe invasive GAS soft-tissue infections 
in humans, even while patients are on 
antibiotic therapy.
The theoretical implication of this 
study is that if intracellular bacteria 
are most commonly found in newly 
involved tissue with low inﬂ  ammation 
and low bacterial load, it might be the 
case that internalization could promote 
the spread of bacteria within the tissue. 
This so-called Trojan horse approach 
is also seen in the ﬁ  sh, and sometimes 
human, pathogen Streptococcus iniae, 
which invades macrophage-like cells 
in a similar way. Studies are currently 
exploring whether this also occurs in GAS 
soft-tissue infections. But in any case, 
the clinical implication of this ﬁ  nding is 
that alternate therapies will be required 
if clinicians are going to improve the 
morbidity and mortality associated with 
severe GAS soft-tissue infections.
Thulin P, Johansson L, Low DE, Gan 
BS, Kotb M, et al. (2006) Viable group A 
streptococci in macrophages during acute 
soft tissue infection. DOI: 10.1371/journal.
pmed.0030053
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Breast cancer is one of the highest-
proﬁ  le diseases in women in developed 
countries. Although the risk for women 
younger than 30 years is minimal, this risk 
increases with age. One-third of all breast 
cancer patients in Sweden, for example, 
are 70 years or older at diagnosis. Despite 
these statistics, few breast cancer trials 
take these older women into account. 
Considering that nowadays a 70-year-
old woman can expect to live for at least 
another 12–16 years, this is a serious gap 
in clinical knowledge, not least because 
in older women breast cancer is more 
likely to be present with other diseases, 
and doctors need to know whether 
cancer treatment will affect or increase 
the risk for these diseases.
In 1992, guidelines were issued to 
the Uppsala/Örebro region in Sweden 
(with a population of 1.9 million) that 
all women with breast cancer should be 
able to receive equal treatment. At the 
same time, a breast cancer register was 
set up to record details about patients in 
the region, to ensure that the guidelines 
were being followed. Sonja Eaker and 
colleagues set out to assess data from the 
register to see whether women of all ages 
were receiving equal cancer treatment.
They compared the 5-year relative 
survival for 9,059 women with breast 
cancer aged 50–84 years. They divided 
them into two age groups: 50–69 years, 
and 70–84 years. They also categorized 
the women according to the stage of 
breast cancer. They looked at differences 
between the proliferative ability of breast 
cancer cells, estrogen receptor status, the 
number of lymph nodes examined, and 
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In the past 10 years, evidence has 
suggested that group A streptococci (GAS) 
adhere to epithelial cells and invade them. 
In 1994, LaPenta and colleagues found 
that GAS could invade human epithelial 
cells, in some cases better than classical 
intracellular bacterial pathogens such as 
Listeria and Salmonella spp. can. 
Several studies quickly conﬁ  rmed this 
landmark ﬁ  nding and produced further 
evidence to support this mechanism. 
One study showed that high-frequency 
invasion needed expression of M protein 
(a surface protein, variation in which 
provides the basis of Lanceﬁ  eld’s method 
of serotyping GAS) and/or ﬁ  bronectin-
binding proteins such as SfbI. Another 
study found that the M1 serotype of GAS 
was particularly adept at intracellular 
invasion of epithelial cells.
It appeared, therefore, that GAS 
could invade human cells using several 
mechanisms, which suggested that 
intracellular invasion played an important 
role in the disease pathogenesis. The 
most direct evidence for intracellular 
invasion came from studies of patients 
with recurrent tonsillitis, when it was 
found that antibiotics failed to eradicate 
streptococci from the throat in about 
30% of cases of pharyngotonsillitis. 
Osterlund and colleagues showed 
that tonsils excised from such patients 
contained intracellular GAS.
The reason for invasion of host cells is 
not clear, although it was suggested that 
streptococci might ﬁ  nd the intracellular 
environment a good place to avoid host 
defense mechanisms. Other theories 
suggested that internalization played a 
role in the carriage and persistence of 
streptococci. Internalization might also 
be involved in the invasion of deeper 
tissues, although some studies have 
found that low virulence was associated 
with internalization.
In this month’s PLoS Medicine, Pontus 
Thulin, Anna Norrby-Teglund, and 
colleagues try to further elucidate the 
mechanism behind GAS pathogenesis 
by examining the in vivo interactions 
between GAS and cells involved in 
innate immune responses. The team 
used human biopsies collected from 
17 patients with soft-tissue infections. 
They found that host phagocytic cells, 
primarily macrophages, were being used 
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Human macrophages are host cells for 
intracellular group A streptococci. The 
ﬁ  gure shows viable (green) bacteria within 
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lymph node involvement. The researchers 
also compared types of treatment—i.e., 
surgical, oncological (radiotherapy, 
chemotherapy, or hormonal)—and the 
type of clinic the patients were treated in.
They found that women aged 70–84 
years had up to a 13% lower chance of 
surviving breast cancer than those aged 
50–69 years. Records for older women 
tended to have less information on their 
disease, and these women were more 
likely to have unknown proliferation and 
estrogen receptor status.
Older women were less likely to have 
their cancer detected by mammography 
screening and to have the stage of 
disease identiﬁ  ed, and they had larger 
tumors. They also had fewer lymph 
nodes examined, and had radiotherapy 
and chemotherapy less often than 
younger patients. Current guidelines are 
vague about the use of chemotherapy 
in older women, since studies have 
included only a few older women so 
far, but this did not explain why these 
women received radiotherapy less 
often. Older women were also less 
likely to be offered breast-conserving 
surgery, but they were more likely to 
be given hormone treatment such as 
tamoxifen even if the tumors did not 
show sign of hormone sensitivity. The 
researchers suggest that this could be 
because since chemotherapy tends 
to be not recommended for older 
women, perhaps clinicians believed that 
tamoxifen could be an alternative.
The researchers admit that one 
drawback of their study is that there was 
little information on the other diseases 
that older women had, which might 
explain why they were offered treatment 
less often than younger patients. 
However, the fact remains that in 
Sweden, women older than 70 years are 
offered mammography screening much 
less often than younger women—despite 
accounting for one-third of all breast 
cancer cases in the country—and those 
older than 74 years are not screened at all.
Eaker and coworkers’ ﬁ  ndings indicate 
that older women are urgently in need 
of better treatment for breast cancer and 
guidelines that are more appropriate to 
their age group. Developed countries, 
faced with an increasingly aging 
population, cannot afford to neglect the 
elderly.
Eaker S, Dickman PW, Bergkvist L, 
Holmberg L, the Uppsala/Örebro Breast 
Cancer Group (2006) Differences in 
management of older women inﬂ  uence 
breast cancer survival: Results from a 
population-based database in Sweden. DOI: 
10.1371/journal.pmed.0030025
DOI: 10.1371/journal.pmed.0030092.g001
The proportion of women diagnosed 
in stage I breast cancer and the 5-year 
cumulative relative survival ratio differ by 
age group
HIV-1 infection has become a chronic, manageable condition 
for patients who can get long-term access to highly active 
antiretroviral therapy (HAART). However, for some patients, 
HAART causes various metabolic complications, including the 
development of dyslipidemia. For example, some protease 
inhibitors (PI), a class of anti-HIV drugs, have been associated 
with elevated levels of cholesterol, triglyceride (TG), and low 
high-density lipoprotein cholesterol (HDL-c).
PI-based HAART has also been associated with increased risk 
for cardiovascular disease, which could, it has been suggested, 
lead to a future epidemic of cardiovascular disease in patients 
with HIV-1 treated with this regimen long term. 
PIs are not the only anti-HIV drugs thought to play a role 
in dyslipidemia. Researchers suspect that non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), a widely used class 
of antiretroviral, may also contribute to the condition. But the 
role of NNRTIs is less clear. The relationship between HIV-1 
infection and its treatment is a complex one that we still do not 
completely understand, and it may have a profound impact on 
the future well-being of this population.
The features of PI-HAART-related dyslipidemia resemble 
familial combined hyperlipidemia (a lipid disorder that runs in 
families and which has a genetic basis), which suggests that 
lipoprotein gene variants might be linked to this condition. 
For example, apoC-III, a protein whose plasma levels are 
directly correlated with TGs in the general population, has 
also been implicated in regulating breakdown of triglyceride-
rich lipoprotein. Several studies have established a complex 
interaction of genetic variation between apoC-III and apoA-I/C-
III/A-IV/AV cluster with plasma TG levels. Two previous studies, 
restricted almost entirely to White individuals, reported a marked 
increase in plasma TG levels in patients with HIV-1 on PI-HAART 
regimens when they also had apoC-III and apoE gene variants. 
Given the worldwide demographics of HIV-1 infection, the 
relationship between PI-HAART-related metabolic events and 
race/ethnicity could be important. The relationship between 
race/ethnicity and lipoproteins has been well described in 
the general population. Race/ethnicity has been considered a 
surrogate for environmental inﬂ  uences on lipids, although recent 
studies have demonstrated that genetic factors also account 
for important differences in plasma lipids across racial/ethnic 
groups. For example, studies have shown that some hepatic 
lipase single nucleotide polymorphisms (SNPs) present only in 
African Americans result in lower enzyme activity, and account 
for a proportion of the racial/ethnic differences in HDL-c levels.
The role of race/ethnicity in metabolic complications in 
individuals with HIV-1 has not really been considered. In a new 
study, Andrea Foulkes and colleagues examined the inﬂ  uence 
of racial/ethnic inﬂ  uences on plasma lipoproteins, and studied 
the genetic effects on lipids in patients with HIV-1. They did 
a cross-sectional analysis of race/ethnicity, apoC-III/apoA-I 
genotypes, and PI exposure on plasma lipids on 626 patients 
participating in several ongoing AIDS Clinical Trial Group studies. 
They found that race/ethnicity was a predictor of plasma lipids in 
Race/Ethnicity, Lipoproteins, and Antiretroviral Therapy 
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Every year, more than 200,000 
Americans die from sepsis, a severe 
illness caused by bacterial infection of 
the bloodstream. In the United States, 
2%–3% of all hospital admissions are 
for sepsis, which has a mortality rate of 
about 30%. In sepsis, pathogens that 
have entered the bloodstream through a 
wound or from an infected organ induce 
a systemic inﬂ  ammatory response, which 
can cause circulatory system damage, 
multiple organ dysfunction, and death, 
particularly in people with other medical 
conditions.
Treatment for sepsis includes 
antibiotics to clear the initiating 
bacteria and to provide medical support 
for damaged organs—mechanical 
ventilation for lung dysfunction, for 
example. However, the prognosis for 
patients would be much better if organ 
dysfunction could be prevented, so 
researchers, including Vikas Sukhatme 
and colleagues, are investigating how 
organs become damaged during 
sepsis. Sukhatme’s team now reports 
results suggesting that a protein called 
angiopoietin-2 may play a pivotal role 
in acute respiratory distress syndrome 
(ARDS), a condition that affects about 
40% of patients with sepsis and worsens 
their prognosis.
ARDS starts with protein-rich ﬂ  uid 
leaking out of the blood capillaries of 
the lung into the alveoli, the terminal 
airspaces where gas exchange normally 
occurs. The presence of this ﬂ  uid in 
the alveoli impairs gas exchange, and 
prevents the lungs from expanding 
and contracting normally during 
breathing. But what causes ﬂ  uid to 
leak out of the vasculature? Capillaries 
are normally lined with endothelial 
cells linked together with adhesive 
junctions to form an impermeable 
barrier. The development of this 
barrier is controlled in part by two 
peptides called angiopoietin-1 (Ang-
1) and angoipoietin-2 (Ang-2). Both 
peptides bind as ligands to a signaling 
receptor called Tie-2. Ang-1 functions 
as an agonist; its binding activates the 
Tie-2 receptor. In contrast, Ang-2 is 
an antagonist, whose binding blocks 
signal transduction. Animal experiments 
have shown that the two ligands 
have opposite functions in vascular 
development: Ang-1 promotes the 
stabilization of nascent blood vessels; 
Ang-2 disrupts this action. These 
ﬁ  ndings, the fact that Tie-2 expression 
may be abnormal in bronchopulmonary 
dysplasia (a developmental lung 
disorder), and the high level of Tie-
2 expression in lungs prompted 
Sukhatme’s team to ask if the Tie-2 
signaling pathway is affected in sepsis 
and, speciﬁ  cally, if excess Ang-2 levels 
might promote the vascular leakage that 
underlies ARDS. 
The researchers measured serum Ang-
2 concentrations in 22 patients admitted 
to the hospital with sepsis, as well as 
in 29 control individuals hospitalized 
with other conditions. Admission levels 
of Ang-2 were higher in patients with 
septic shock (characterized by low blood 
pressure) or multiorgan failure than in 
control patients or in patients with sepsis 
alone. Over time, Ang-2 levels mirrored 
the clinical course of illness in individual 
patients, increasing as they became more 
sick and declining as they recovered. 
Finally, Ang-2 levels correlated with 
impaired lung function. These results are 
consistent with the idea that increased 
circulating Ang-2 might contribute to 
vascular leakage in sepsis.
To test their hypothesis further, 
the researchers turned to thin sheets 
(monolayers) of cultured endothelial 
cells. The addition of patient serum 
containing high levels of Ang-2 (but not 
serum containing low levels) to these 
monolayers caused changes in the 
actomyosin cytoskeleton (a network of 
proteins that forms the cellular skeleton). 
These structural changes, which resulted 
in the endothelial cells contracting and 
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Ang-2 causes intercellular gaps in cultured 
endothelial cells
patients with HIV-1 on HAART. Overall, Black patients on HAART 
had a less atherogenic lipid proﬁ  le than White and Hispanic 
patients. The authors believe their ﬁ  nding was consistent with 
epidemiological data in non-HIV-1 populations, and could be of 
particular importance given the global spread of HIV-1 infection, 
especially in sub-Saharan Africa. They also found that in Hispanic, 
but not in White or Black, patients, apoC-III gene variants were 
associated with less dyslipidemia in patients exposed to PI-
containing HAART.
Foulkes and colleagues say their ﬁ  ndings are the ﬁ  rst evidence, 
to their knowledge, for race/ethnicity–speciﬁ  c differences in 
both the occurrence of dyslipidemia on antiretroviral therapy 
(ART) and the inﬂ  uence of genetic factors on the prevalence of 
PI-related lipid abnormalities. But they stress that the ﬁ  ndings do 
not imply that “race” was responsible for functional differences 
between gene variants. Rather, it is much more likely that 
differences relate to variation in the linkage disequilibrium (the 
inheritance pattern of blocks of DNA, or haplotypes, over time) 
in apoC-III, which they found to vary with race/ethnicity, or to 
the confounding inﬂ  uences of additional environmental and/or 
genetic factors.  
Putting race/ethnicity aside, the authors rightly point 
out that any strategy that identiﬁ  es individuals with HIV-1 
at increased risk of ART-related metabolic complications 
will improve decision making for selecting appropriate ART 
regimens and preventive cardiovascular therapies, and 
ultimately will decrease the long-term cardiovascular risk of 
these patients. In addition, they emphasize that such strategies 
have to be assessed in studies that include adequate numbers 
of individuals within all racial/ethnic groups in order to 
determine their generalizability and utility in the worldwide 
population of patients with HIV-1.  
Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, et al. (2006) 
Associations among race/ethnicity, apoC-III genotypes, and lipids in 
HIV-1-infected individuals on antiretroviral therapy. DOI: 10.1371/
journal.pmed.0030052
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gaps forming between them, could 
be replicated by the addition of Ang-
2 alone, and were accompanied by 
increased permeability of the endothelial 
monolayer. Adding Ang-1 reversed the 
effects of Ang-2 on the endothelial cells. 
Further experiments indicated that Ang-2 
activated a protein called Rho-kinase and 
the subsequent addition of phosphate 
groups to myosin light chain, a protein 
involved in cell contraction. In the last 
set of experiments, the researchers 
showed that systemic administration 
of Ang-2 to healthy mice increased 
vascular permeability and caused ﬂ  uid 
extravasation in their lungs, changes 
reminiscent of early ARDS. 
These results support a role of Ang-2 
in sepsis-associated ARDS, and suggest 
new targets for the treatment of sepsis. 
Up until now, the emphasis has been on 
damping down the systemic immune 
response, but drugs that do this often 
have unwanted side effects. Targeting 
Tie-2 signaling might be a cleaner way 
to deal with the leaky vasculature that 
causes ARDS and other aspects of sepsis. 
In addition, suggest Sukhatme and 
colleagues, serial Ang-2 measurements 
might identify which patients at risk of 
developing ARDS would beneﬁ  t most 
from therapy aimed at preventing 
vascular leakage. But, they acknowledge, 
further experiments are needed to 
prove conclusively that Ang-2 plays a 
causal role in human ARDS, to clarify 
why the lungs are especially susceptible 
to systemic excess levels of Ang-2, and 
to test whether interfering with Ang-2 
function can yield therapeutic beneﬁ  ts. 
Parikh SM, Mammoto T, Schultz A, Yuan 
HT, Christiani D, et al. (2006) Excess 
circulating angiopoietin-2 may contribute to 
pulmonary vascular leak in sepsis in humans. 
DOI: 10.1371/journal.pmed.0030046
All cells require an adequate supply of oxygen to 
function. Oxygen is used in aerobic metabolism, which turns 
carbohydrates into the energy needed to power essential 
cellular processes such as protein synthesis. Cells, therefore, 
have to sense and respond to hypoxia—inadequate oxygen 
levels. In mammalian cells, a family of transcription factors 
(proteins that control when genes are transcribed) called 
hypoxia-inducible factors (HIFs) are particularly important in 
orchestrating cellular responses to hypoxia.
HIF-1—the ﬁ  rst HIF to be identiﬁ  ed—contains two subunits. 
HIF-1β is expressed all the time; HIF-1α is an oxygen-sensitive 
inducible subunit. When there is sufﬁ  cient oxygen (normoxic 
conditions), enzymes called prolyl hydroxylases add hydroxyl 
groups to HIF-1α. This leads to the recognition of HIF-1α by 
von Hippel–Lindau (VHL) protein, which then adds a molecular 
tag to HIF-1α that targets it for destruction. When oxygen 
is limiting, the prolyl hydroxylases cannot work, so HIF-1α 
escapes destruction and forms an active transcription factor 
by dimerizing with HIF-1β. This induces the expression of 
numerous target genes that help cells to survive hypoxia. HIF-
1α can also escape destruction in normoxic conditions if the 
VHL protein is defective or missing.
As well as their important role in normal cells, hypoxia 
responses are also important in many human diseases. 
In cancer, the lack of oxygen deep within the tumor or 
genetic changes can induce a strong hypoxia response that 
helps the tumor to grow faster, and reduces the efﬁ  cacy of 
chemotherapy and radiotherapy. But, despite the importance 
of the hypoxia response in sickness and in health, it is 
known that a hypoxia response does not affect all tissues 
evenly. But little is known about how different cell types 
respond to hypoxia. DNA microarrays (“gene chips” that 
can synchronously interrogate thousands of genes for their 
expression levels) have proven to be very valuable tools to 
evaluate the similarity and differences between cell types. 
Jen-Tsan Chi, Zhen Wang, Patrick Brown, and an international 
team of researchers have remedied this by examining global 
changes in gene-expression programs in response to hypoxia 
in several different cell types.
The researchers grew four human cell types in normoxic, 
hypoxic, or anoxic conditions and determined which genes 
were expressed in each condition using DNA microarrays. They 
then used a mathematical approach to identify genes whose 
expression under hypoxic conditions varied according to cell 
type. They found that the expression of many more genes 
was induced in kidney epithelial cells than in breast epithelial 
cells; fewer genes still were induced in nonepithelial cells. 
To understand physiological and pathological responses to 
oxygen variability, it will be necessary to ﬁ  nd out exactly what 
drives these tissue- and cell type–speciﬁ  c differences. For now, 
though, the researchers report that the vigorous transcriptional 
response to hypoxia in renal epithelial cells was, in part, due 
to high levels of HIF-1α expression in these cells. They also 
suggest that this strong hypoxia response may explain why 
patients with VHL disease, who have a mutated VHL gene, 
develop mainly kidney tumors.
The researchers next used gene-expression data from renal 
and breast epithelial cells to derive a gene-expression signature 
of the epithelial hypoxia response. Because tumor hypoxia is an 
important factor in human cancer progression, the researchers 
reasoned that such a signature might help to predict clinical 
outcomes in patients with various carcinomas (epithelial cell 
tumors). For kidney, breast, and ovarian cancers, the signature 
allowed the researchers to divide tumors into a high hypoxia 
Hypoxia Responses: How Different Cells and Tumors React to Oxygen Shortage
DOI: 10.1371/journal.pmed.0030105
DOI: 10.1371/journal.pmed.0030105.g001
Hypoxia score is associated with patient survival
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response group and a low hypoxia response group. For breast 
and ovarian cancer, a high hypoxia response correlated with 
poor outcome.
Finally, Chi and colleagues investigated whether the gene-
expression signature of hypoxia could indicate the likely 
outcome for patients any better than existing prognostic 
factors (for example, tumor size and grade). Their results 
indicated that the information provided by the hypoxia 
signature was more predictive than any of the clinical 
parameters currently in use, and independent of predictive 
information provided by a “wound” gene-expression signature 
constructed in a similar way. The researchers conclude that 
by integrating gene-expression characteristics of tumors 
with genetic changes and clinical data, it should be possible 
to build up a detailed biological proﬁ  le of individual tumors 
that could be used both to predict their clinical course and to 
choose appropriate general or targeted therapies (for example, 
drugs designed to inhibit HIF activity) when these become 
available. 
Chi JT, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, et al 
(2006) Gene expression programs in response to hypoxia: Cell 
type speciﬁ  city and prognostic signiﬁ  cance in human cancers. DOI: 
10.1371/journal.pmed.0030047
Many cases of thrombocytopenia in 
adults are diagnosed incidentally after a 
routine blood cell count; more efﬁ  cient 
laboratory processes have meant that 
an increasing number of asymptomatic 
individuals with borderline low platelet 
counts (100 × 109/l to 150 × 109/l) are 
now being identiﬁ  ed. There are gaps in 
our knowledge of this condition, and 
the natural history of thrombocytopenia 
has not been systematically studied. 
For example, it’s not known how many 
people might develop other diseases 
associated with a low platelet count, or 
how many people can live outwardly 
healthy lives with borderline normal 
platelet counts. In the absence of other 
diseases, current treatment guidelines are 
based on expert opinion rather than on 
randomized controlled trials, and patients 
are treated if they have severe bleeding 
and/or extremely low platelet counts. 
One cause of an asymptomatic 
low platelet count is an immune 
thrombocytopenia (ITP), either 
primary (idiopathic) or secondary 
to an autoimmune disorder. Hence, 
thrombocytopenia might be the start of a 
systemic autoimmune disease, which can 
make it difﬁ  cult to diagnose secondary 
immune thrombocytopenia from ITP. 
Systemic autoimmune diseases could be 
treated if detected early.
In this month’s PLoS Medicine, Roberto 
Stasi and colleagues followed the 
natural history of 260 apparently healthy 
adults who had low platelet counts and 
were considered to have “borderline 
thrombocytopenia.” After six months 
of monitoring to see if the condition 
persisted, 191 patients were monitored 
for, on average, 64 months. In 64% 
of these patients, thrombocytopenia 
resolved spontaneously or persisted 
with no other disorders becoming 
apparent. In the remainder, the most 
frequent event was the development 
of an autoimmune disease. The 10-year 
probability of developing idiopathic ITP 
was 6.9% and of developing autoimmune 
disorders other than ITP was 12%. Among 
36 patients (14%) with stable normal 
platelet counts, most (23/36) improved 
their counts during the initial six-month 
assessment. This pattern might be 
because they had a “silent” viral infection 
or a minor insult of a different nature to 
the bone marrow, the authors suggest. 
Another theory is that these patterns 
might also be due to seasonal variation of 
the platelet count. 
Interestingly, in this study many 
patients with a low platelet count 
who developed autoimmune disease 
did not have conventional markers of 
autoimmunity. This ﬁ  nding conﬂ  icts with 
previous work that has suggested that 
autoantibodies are present many years 
before the diagnosis of systemic lupus 
erythematosus. Speciﬁ  cally, two patients 
in this study who developed systemic 
lupus erythematosus did not have 
detectable autoantibodies.
Many patients with low platelet count 
also had chronic thyroiditis. Based on 
previous evidence, the relationship 
between autoimmune thrombocytopenia 
and chronic thyroiditis is controversial, 
and the occurrence of patients with 
chronic thyroiditis with borderline 
thrombocytopenia (7%) was not higher 
than the general population (6.2%). 
Patients with chronic thyroiditis did not 
have a higher risk of developing ITP or 
other autoimmune disorders than the 
other individuals, the authors say.
Long-Term Outcome of Individuals with Borderline Thrombocytopenia
DOI: 10.1371/journal.pmed.0030093
DOI: 10.1371/journal.pmed.0030093.g001
Microphotograph of a megakaryocyte from an individual who developed ITP
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This study will improve clinicians’ 
understanding of the natural history of 
borderline thrombocytopenia, although 
exactly what these ﬁ  gures mean for 
individuals is hard to judge because 
there was no control group. The authors 
acknowledge that much more needs 
to be done. For example, for conditions 
such as ITP, diagnosis is still by exclusion, 
so other diseases that might cause 
thrombocytopenia have to be ruled 
out. Further work will need to be done 
to establish whether the risk for these 
patients of developing an autoimmune 
disease is higher than in the general 
population and, most practically, whether 
intensive follow-up has a positive impact 
on patients’ prognosis.
Stasi R, Amadori S, Osborn J, Newland 
AC, Provan D (2006) Long-term outcome 
of otherwise healthy individuals with 
incidentally discovered borderline 
thrombocytopenia. DOI: 10.1371/journal.
pmed.0030024
Between 750,000 and 1 million people 
in the United States are addicted to 
heroin, a semisynthetic opioid made 
from the seeds of opium poppies. 
This highly addictive, illegal drug is 
converted in the brain into morphine, 
which binds to opioid receptors (which 
normally bind pain-relieving peptides 
produced by the brain) to produce 
a euphoric rush or heroin “high.” 
Repeated heroin use causes drug 
dependency—increasing amounts 
of the drug are needed to achieve its 
pleasurable effects, and its removal 
rapidly produces unpleasant withdrawal 
symptoms (“lows”) that can last for 
several days to months. Users become 
addicts when their desire to take heroin 
outweighs the negative health, social, 
ﬁ  nancial, and legal consequences of 
their drug habit.
For more than 30 years, the synthetic 
narcotic (a drug that induces sleep) 
methadone has been used to treat 
heroin addiction. Methadone, a powerful 
pain-relieving drug, binds to the 
same receptors as heroin but without 
producing the euphoric rush. Because 
it lasts much longer in the body than 
heroin, patients trying to abstain from 
heroin need to take only a single daily 
dose of methadone to avoid withdrawal 
symptoms. Although patients become 
physically dependent on methadone, 
the reduction in withdrawal symptoms, 
together with a reduction in drug 
cravings, helps heroin addicts in 
methadone maintenance treatment 
programs stop using illicit drugs and lead 
normal lives.
The minimum maintenance dose of 
methadone recommended in these 
programs—60mg/day—is derived from 
randomized trials that have tested the 
ability of different doses of methadone to 
wean populations of addicts off heroin. 
However, many clinicians report that 
lower doses of methadone are effective 
in some patients. To test whether there 
is scientiﬁ  c evidence for these anecdotal 
observations, Jodie Trafton, Jared 
Minkel, and Keith Humphreys undertook 
a prospective observational study of 
individual responses to methadone 
treatment. They now report that setting 
a standard dose will not optimize 
therapy for all patients, and recommend 
that methadone doses be titrated on 
an individual basis to achieve heroin 
abstinence. 
The researchers studied 222 volunteers 
addicted to heroin for a year after 
they started methadone treatment at 
eight clinic sites. Four of these sites 
regularly dosed patients with more 
than the recommended minimum 
daily methadone dose, and four dosed 
a signiﬁ  cant number of patients with 
lower doses. Overall, 168 volunteers 
achieved heroin abstinence for at least a 
month, as measured by the absence of 
illicit opioids in their urine. The median 
effective daily dose of methadone taken 
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by these successful volunteers was 69 
mg, but doses ranged from 1.5 to 191.2 
mg. Of those who abstained, 16% took 
daily doses of more 100 mg methadone, 
38% remained abstinent on less than the 
recommended minimum daily dose, and 
almost half of the patients who did not 
achieve abstinence received more than 
60 mg/day of methadone. 
Trafton and colleagues also 
investigated the factors that might 
affect the methadone dose needed to 
achieve heroin abstinence. How long 
a patient had taken heroin and the 
amount taken per day did not correlate 
with the methadone dose associated 
with abstinence. However, patients 
who had previously been through drug 
detoxiﬁ  cation treatments appeared 
to need higher methadone doses, as 
did those recently diagnosed with 
depression or posttraumatic stress 
disorder and those living in areas with 
lower average heroin purity. In addition, 
patients who were abstinent on higher 
doses were more likely to have stayed 
in treatment longer or attended a 
clinic where dose reductions were 
discouraged. Taken together, these 
factors predicted 40% of the variance 
in methadone dosage associated 
with heroin abstinence. The results 
suggest that only patients with lower 
methadone needs achieve abstinence 
in the early titration phase of treatment 
or at clinics that encourage use of lower 
doses. 
These results provide scientiﬁ  c 
conﬁ  rmation that the dose of methadone 
required to achieve heroin abstinence 
varies greatly between patients, and 
indicate that effective and ineffective 
dose ranges overlap substantially. The 
researchers suggest that clinicians 
should be allowed some ﬂ  exibility in 
determining methadone dosing and 
call for research into the most effective 
way to determine the optimal dose for a 
particular patient. For now, they suggest, 
given that patients attending clinics that 
routinely give at least the recommended 
minimum dose of methadone do better 
on average than those attending clinics 
where lower doses are often given—60 
mg/day should be the benchmark for 
dose titration, which should occur early 
during treatment. 
Trafton JA, Minkel J and Humphreys K 
(2006) Determining effective methadone 
doses for individual opioid-dependent 
patients. DOI: 10.1371/journal.
pmed.0030080
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Long-standing inequities exist in the amount of research 
on diseases that affect the developed world and those—such 
as leishmaniasis and schistosomiasis—that affect nonwhite 
populations who live in the developing world. These inequities 
have also been perceived to exist when white and nonwhite 
populations coexist in developed countries.
Ethnic groups differ in their susceptibility to particular 
diseases. These differences can be genetic—the result of gene 
mutations that are more prevalent in some ethnic groups. They 
may also be due to social factors—in industrialized countries, 
for example, ethnic minorities are often poorer, less educated, 
and more frequently unemployed than their white counterparts. 
Studies in white populations, therefore, cannot necessarily be 
extrapolated to other ethnic groups.
Cardiovascular disease is a major cause of death for all ethnic 
groups in developed countries, and the risk is especially high in 
those originating from South Asia. In the UK, for example, early 
deaths from coronary heart disease in Indians, Bangladeshis, 
Pakistanis, and Sri Lankans are about 50% higher than the 
national average. For Caribbeans and West Africans, on the other 
hand, the rates are much lower than average.
Meghna Ranganathan and Raj Bhopal systematically reviewed 
the scientiﬁ  c literature over the past decades to assess the 
extent to which different ethnic minorities were included in 
cardiovascular cohort studies in Europe and North America. 
They identiﬁ  ed 72 studies, 39 of which started after 1975 (at 
that time, it was well-known that different ethnic groups have 
different risk factors, and quite a bit was known about causes 
and control of the disease in white populations). Forty-one 
studies were conducted in Europe and 31 in North America, and 
one study involved participants from both continents. 
Overall, the researchers found, there is little information on 
cardiovascular research in ethnic populations—just ten studies 
compared white and nonwhite populations, and only ﬁ  ve focused 
on one nonwhite ethnic group. All 15 of those were conducted in 
the United States. Despite the high risk of cardiovascular disease 
in ethnic minorities in Europe, not one European study so far has 
investigated the disease speciﬁ  cally in these populations. 
In general, it seems that issues of race or ethnicity have rarely 
been taken into account. Decisions about which ethnic groups to 
include were not often a part of the study design nor were they 
made explicit in the study report, and few articles gave details 
of the ethnic composition of the study population. Even when 
nonwhite participants were included in studies, there were often 
too few of them to allow for analysis by ethnicity.
In some cases, researchers were open about their aim to study 
only white populations. In others, by selecting participants based 
on employment status or by conducting studies in rural settings, 
researchers were unlikely to include many participants from 
nonwhite ethnic groups that tend to cluster in cities. 
In cardiovascular disease, in particular, clear ethnic variations 
in risk mean that studying nonwhite populations is crucial if their 
health needs are not to be neglected, say the authors. 
The ﬁ  rst step toward better understanding why some ethnic 
groups are more susceptible to disease is acknowledging 
the need for studying the question. Because such studies are 
expensive and challenging, say Ranganathan and Bhopal, they 
will only be done when there is a demand for them. 
Ranganathan M, Bhopal R (2006) Exclusion and inclusion of 
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The incidence of methicillin-resistant Staphylococcus 
aureus (MRSA) in hospitals continues to rise globally. S. aureus 
infections, including MRSA, occur most frequently in patients 
with weakened immune systems in hospitals and healthcare 
facilities, such as nursing homes and dialysis centers. Healthcare-
associated S. aureus infections include surgical-wound infections, 
bloodstream infections, and pneumonia. Factors associated with 
the spread of MRSA infections in hospitals include skin-to-skin 
contact, wounds, contaminated items and surfaces, and poor 
hygiene. Control measures have focused on hand hygiene, 
restriction of antibiotics, and the detection and isolation of 
colonized and infected patients.
Strains resistant to methicillin are a major concern in hospitals 
because of the high mortality rate associated with infections 
caused by them and the stringent hygienic requirements needed 
for patients who carry MRSA. Experts say the focus of most 
national guidelines is the detection and isolation of colonized 
and infected patients. However, developing rapid detection 
techniques has not been easy.
Outbreaks are usually identiﬁ  ed from laboratory test 
results and patients’ charts—a time-consuming procedure. In 
established outbreaks, molecular typing (e.g., pulsed-ﬁ  eld gel 
electrophoresis [PFGE]) is usually used to track the outbreak. To 
improve the speed of typing, DNA sequence-based approaches, 
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such as multi-locus sequence typing (MLST), are being used 
but are still too expensive for routine use and have lower 
discriminatory power compared with PFGE.
Frenay et al. became the ﬁ  rst group to use a single-locus 
sequence typing method for S. aureus, by using the sequence 
of the polymorphic region X of the S. aureus protein A gene 
(spa) for typing. However, the full potential of this method 
has not been exploited thus far. Recently, however, a software 
program was developed so that the spa sequences could be 
analyzed automatically and linked to a database integrated with 
epidemiological information.
In this month’s PLoS Medicine, Alexander Mellmann, Dag 
Harmsen, and colleagues compared this approach with 
classical surveillance techniques (frequency, and infection 
control professional [ICP] alerts) to investigate whether an 
automated system could complement or replace the labor-
intensive traditional methods. The study, performed at a German 
tertiary hospital from 1998–2003, found that only ﬁ  ve of the 
13 “true” clusters were detected as clusters by visual screening 
of laboratory reports by the ICP. By contrast, clonal alerts (spa 
typing and epidemiological data) were more sensitive than the 
classical techniques.
The authors suggest that spa typing and automated alerts 
could offer a useful early-warning system, which could also 
be used to model infection dynamics and estimate important 
epidemiological parameters. The combination of medical 
informatics and molecular laboratory techniques could help 
clinicians prevent limited clusters of preventable MRSA from 
expanding into large-scale outbreaks. Laboratory-based 
surveillance has another advantage: clusters occurring 
throughout the hospital could be identiﬁ  ed at a single, central 
data-collection point.
One limitation of clonal alerts and classical techniques, 
however, is that they all rely on pre-deﬁ  ned rules, which means 
that unusual patterns of outbreaks might go undetected. A 
way to get around this limitation might be to use data mining 
of patient information databases to look for patterns missed 
by traditional analysis. Researchers in the United Kingdom 
recently proposed to use data from hundreds of National 
Health Service wards for such data mining. The data analyzed 
by the researchers includes the number of infected patients on 
a ward, the type of treatments they received, and the hygiene 
and quarantine rules used by hospital staff to avoid or control 
infections. However, Mellmann and colleagues raise concerns, 
saying that although these data-mining “discovery” models are 
independent of an underlying hypothesis, they are usually less 
sensitive and speciﬁ  c, and once the unusual becomes usual it is 
no longer detected. Nonetheless, what is clear is that the days of 
infection outbreaks being detected solely by vigilant infectious-
disease clinicians are over. 
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